Outcome of Patients with Hepatitis C Virus-related Single, Small Hepatocellular Carcinoma

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4191-4196

  Sako, Katsumi ^a   Komorizono, Yasuji ^a   Oketani, Makoto ^b   Hasegawa, Susumu ^b   Yamasaki, Naruhiro ^b   Shibatou, Toshihiko ^b   Maeda, Masahiko ^b   Kohara, Kazunori ^b   Shigenobu, Shuhou ^b   Yasunari, Hiramine ^b   Sakurai, Kazuhiro ^b   Hiwaki, Takuya ^b   Ishibashi, Kazuaki ^b   Arima, Terukatsu ^b  

^a Nanpuh Hospital   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

HCC; HCV; Recurrence; Single; Survival

Indexed keywords

ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; BIOSAFETY; CANCER CELL; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER ABLATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXPERIMENTAL TEST; FEMALE; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LIVER CELL; LIVER CELL CARCINOMA; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTE COUNT; TRANSCATHETER CHEMOEMOBILZATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0344009649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N and Houghton M: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2: 1006-1008, 1989.
2. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M and Bru C: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 335: 300-302, 1990.
3. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo QL and Kuo G: Hepatitis C-associated hepatocellular carcinoma. Hepatology 12: 589-591, 1990.
4. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, Tsuji T, Yano M, Kuo G and Choo QL: Japanese Red Cross Central Blood Center, Tokyo. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67: 429-433, 1991.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138): 1426-1432, 1998.
6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S and Albrecht JK: Related articles, links interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21): 1485-1492, 1998.
7. Komorizono Y, Sako K, Yamasaki N, Hiwaki T, Sakurai K, Shibatou T, Maeda M, Kohara K, Shigenobu S, Hasegawa S, Arima T, Oketani M, Ishibashi K and Arima T: Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res 22(6B): 3573-3578, 2002.
8. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R and Rodes J: Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12: 753-760, 1990.
9. Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751-755, 1998.
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649, 1973.
11. Llovet JM, Vilana R, Bru C et al: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33: 1124-1129, 2001.
12. Rossi S, Garbagnati F, Lencioni R et al: Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217: 119-126, 2000.
13. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K and Ueno Y: Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 351: 1773-1777, 1998.
14. Tsuda H, Oda T, Sakamoto M and Hirohashi S: Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res 52: 1504-1509, 1992.
15. Miyagawa S, Kawasaki S and Makuuchi M: Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 24: 307-310, 1996.
16. Takenaka K, Yamamoto K, Taketomi A, Itasaka H, Adachi E, Shirabe K, Nishizaki T, Yanaga K and Sugimachi K: A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1: 20-24,1995.
17. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M et al: Related articles, books, linkout characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 4 Pt 1: 1027-1033, 1995.
18. Takano S, Yokosuka O, Imazeki F, Tagawa M and Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 3: 650-655, 1995.
19. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M and Sassa T: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1: 87-92, 1997.
20. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, Boix L, Visa J and Rodes J: Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection, Hepatology 5: 1121-1126, 1993.
21. Daniele B, De Sio I, Izzo F, Capuano G, Andreana A, Mazzanti R, Aiello A, Vallone P, Fiore F, Gaeta GB, Perrone F, Pignata S and Gallo C: Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: A cancer of the liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol 1: 63-67, 2003.
22. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L and Gazelle GS: Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210(3): 655-61, 1999.
23. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11): 693-699, 1996.
24. Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211(3): 277-287, 1990.
25. Leypold J, Kriz Z, Privara M, Horvath V and Dvorak M: Assessment of functional capability of liver parenchyma using indocyanine green before liver resection. Bratisl Lek Listy 102(2): 115-116, 2001.
26. Nonami T, Nakao A, Kurokawa T, Inagaki H, Matsushita Y, Sakamoto J and Takagi H: Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Hepatogastroenterology 46(27): 1669-1672, 1999.